• Explore /
  • Poster
  • / Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in<em> </em>advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.

Abstract Poster

Authors

Masayuki Takeda

Masayuki Takeda

Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka-Sayama, Japan

Masayuki Takeda , Takashi Seto , Hidetoshi Hayashi , Morihito Okada , Koichi Azuma , Shunichi Sugawara , Haruko Daga , Tomonori Hirashima , Kimio Yonesaka , Yoshiko Urata , Haruyasu Murakami , Haruhiro Saito , Akihito Kubo , Toshiyuki Sawa , Eiji Miyahara , Naoyuki Nogami , Takeharu Yamanaka , Yoichi Nakanishi , Kazuhiko Nakagawa , Isamu Okamoto

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

000004715

Citation

J Clin Oncol 33, 2015 (suppl; abstr 8056)

DOI

10.1200/jco.2015.33.15_suppl.8056

Abstract #

8056

Poster Bd #

379

Abstract Disclosures

Similar Posters

First Author: Shintaro Kanda

First Author: Richard D. Kim

First Author: Brian M. Slomovitz

First Author: Jun Ni